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Abstract: Equivalent dose from neutrons produced during proton radiotherapy increases
the predicted risk of radiogenic late effects. However, out-of-field neutron dose is not taken
into account by commercial proton radiotherapy treatment planning systems. The purpose of
this study was to demonstrate the feasibility of implementing an analytical model to calculate
leakage neutron equivalent dose in a treatment planning system. Passive scattering proton
treatment plans were created for a water phantom and for a patient. For both the phantom
and patient, the neutron equivalent doses were small but non-negligible and extended far
beyond the therapeutic field. The time required for neutron equivalent dose calculation
was 1.6 times longer than that required for proton dose calculation, with a total calculation
time of less than 1 h on one processor for both treatment plans. Our results demonstrate that it
is feasible to predict neutron equivalent dose distributions using an analytical dose algorithm
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for individual patients with irregular surfaces and internal tissue heterogeneities. Eventually,
personalized estimates of neutron equivalent dose to organs far from the treatment field may
guide clinicians to create treatment plans that reduce the risk of late effects.
Keywords: neutron; dose algorithm; equivalent; proton; therapy; stray dose

1. Introduction
Commercially available proton treatment planning systems (TPSs) typically calculate absorbed dose
using pencil beam algorithms that model charged particle radiation transport. Absorbed dose from
neutrons is implicitly included in the calculation of dose to tissues inside the therapeutic radiation field;
however, neutron equivalent dose outside of the therapy field is usually neglected. This unaccounted for
dose has the potential for harm, as neutron exposures are known to contribute to the risk of long-term side
effects of proton therapy, including the development of secondary malignant neoplasms (SMNs). Hence,
there is a need to develop the capability to predict out-of-field neutron equivalent dose using TPSs.
As cancer screening, diagnosis, and therapy improve, and cancer patients live longer, the potential
for late effects also grows. The Surveillance, Epidemiology, and End Results program reports that, as of
2009, over 12 million cancer survivors were living in the United States [1], and approximately one-half
of all cancer patients received radiation therapy at some stage of their treatment. The 5-year survival rate
of children with all cancers has increased over the past four decades from 60% to nearly 80% [2,3]. For
these patients, the cumulative incidence for SMNs 30 years after childhood cancer diagnosis was found
to be 7.9% [4]. Given the large and increasing number of cancer survivors who received radiotherapy,
there is an urgent need to better understand and mitigate against the risks from stray radiation [5,6].
Measurements indicate that the equivalent dose from neutrons produced from proton treatments is
relatively low, typically less than 1% of the prescribed dose, throughout the entire patient [7–10].
Nevertheless, in organs far from the treatment field, neutrons are the main contributors to equivalent
dose, and they, therefore, govern the risk of radiation-related late effects in those organs. To better
understand neutron equivalent dose distributions, many groups have conducted Monte Carlo simulation
studies [11–20]. Although Monte Carlo simulations benchmarked against measurements showed
good agreement [9,12,14,21–23], Monte Carlo simulation of neutron equivalent dose for individual
patients is complex and time consuming, requiring hundreds of CPU-hours for a single patient
calculation [16,17,24,25]. To allow fast calculation of neutron equivalent dose for individual patients,
Zheng et al. [26] developed an analytical model by fitting Monte Carlo simulated neutron equivalent
dose distributions in air. The model was subsequently extended to account for attenuation of neutrons
in water [27] and, later, to explicitly model neutrons characterized as either intranuclear-cascade,
evaporation, epithermal, or thermal [28]. Anferov [29] also developed an analytical model to predict
equivalent dose from secondary neutrons produced by protons stopping in the treatment nozzle and a
phantom. However, these previous studies did not account for individual patient anatomy, i.e., irregular
exterior surfaces and internal heterogeneities. Consequently, there is incomplete knowledge of the
computational time required to calculate out-of-field secondary neutron dose with an analytical algorithm
in clinically realistic, voxelized representations of patient anatomy.
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The aims of this study were to demonstrate the feasibility of implementing an analytical model
for neutron equivalent dose in a TPS and to estimate the additional computation time required. To
accomplish these aims, we implemented an analytical neutron dose model in a research TPS and
extended the model to take into account the dosimetric effects of irregular surface contours and
heterogeneous patient anatomy. We also compared calculation times using our analytical model with
those done using a Monte Carlo simulation model.
2. Methods
In this study, we extended the neutron dose equivalent analytical model from Pérez-Andújar et al. [28]
to take into account individual patient anatomy. We begin our report by briefly reviewing the analytical
model (hereafter referred to as the H/D model) and then describe our extensions of the H/D model to
take into account irregular surfaces and internal heterogeneities in a patient. Finally, we describe how
we implemented our modified H/D model in a TPS and tested its feasibility for calculating neutron
equivalent dose from passively scattered proton treatments in a water-box phantom and a voxelized
representation of a patient.
2.1. Analytical Model for Neutron Equivalent Dose
Neutron equivalent dose, H, in water per prescribed proton dose, D, (prescribed to a point at isocenter
in a water phantom) was modeled following Pérez-Andújar et al. [28] as:
−p

(H/D)x,y,z = (H/D)iso (d/diso )

4
X

Ci exp [− αi (d − diso )] exp [− (x2 + y 2 )d2iso /(2σi2 z 2 )]

(1)

i=1

where (H/D)iso is the neutron equivalent dose per proton absorbed dose at isocenter, which we determined
for modulated proton beams using:
(H/D)iso =

N
1 X

nmax j=1

(H/D)iso,j nj

(2)

where the proton beam is conceptually divided into N finite energy bins, i.e., that cover the range of
proton energies incident on the patient; nj is the number of protons in the jth energy bin, and nmax is
the number of protons in the maximum energy bin. Monoenergetic (H/D)iso,j values were taken from
Pérez-Andújar et al. [28] as well as the additional fitting parameters required (p, Ci , αi , σi ). This model
allowed calculation of neutron equivalent dose at a point (x, y, z) that is a distance, d, from the virtual
neutron source with a path-length of d’ in water. For this model, we consider the virtual neutron source
to be on central axis on the downstream plane of the patient-specific collimator.
2.2. Attenuation of Neutrons Due to Irregular Surfaces and Heterogeneous Tissues
To extend the capability of the H/D model to predict neutron dose for voxelized representations of
a patient’s anatomy, we used a ray-tracing method [30] to calculate attenuation of the neutron dose
distribution in heterogeneous tissues. The voxelized anatomy was derived from computed tomography
(CT) images of a patient. The attenuation pathlength term d’ in Equation (1) was calculated taking into
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account irregular patient surfaces and heterogeneous tissue densities. Rays were cast that originated
at the virtual neutron source, and they were terminated at the calculation point, e.g., the center of a
voxel. The total attenuation pathlength at the calculation point was computed by summing the individual
attenuation pathlengths of each traversed voxel.
2.3. Implementation of the Analytical H/D Model in a TPS
The extended analytical model for H/D was implemented in a research version of the 4D TPS for
ion therapy (TRiP) [31,32] using the C programming language. The existing ray-tracing algorithm in
TRiP was adapted for the H/D model to determine the water-equivalent depth d’ at each calculation
point as well as the geometric parameters (x, y, z, and d) with respect to the central-point at the plane of
collimation, where a large majority of neutrons striking the patient originate. These calculations were
performed sequentially to find H/D for each voxel of the patient CT. The pencil beam dose algorithm in
TRiP was used to calculate absorbed dose, D, from protons for the passive scattering proton treatment
plan. Because TRiP was developed for scanned-beam applications, passive scattering was simulated by
creating an artificial planning target volume, PTVPS that mimicked scattered beam delivery. To achieve
this, an aperture was defined using the boundary of the original PTV projected to beam’s eye view.
Within this aperture, the maximal difference between radiological depths of the proximal and distal
edges of the PTV was determined, i.e., the range modulation width of the PTV. To form the PTVPS , we
included all voxels that were within the aperture and upstream of the distal PTV edge within the range
modulation width. Finally, a scanned-beam treatment plan was optimized for the generated PTVPS ,
mimicking a passive scattering treatment plan.
2.4. Calculation of Equivalent Dose Distributions from Neutrons in a Water Phantom
A box-shaped water phantom (30 × 15 × 15 cm3 ) was created that contained a spherical target 5 cm
in diameter at a depth of 7.5 cm. A single proton treatment field was designed to uniformly irradiate
the target. Proton absorbed dose was converted to equivalent dose using a mean radiation weighting
factor of 1. Equivalent dose distributions were computed for the water phantom for (1) protons only
and (2) the combined contribution from protons and neutrons. Three-dimensional (3D) equivalent dose
distributions were visualized using multiple 2D figures of equivalent dose using colorwash and contour
plots. Calculation time was recorded for both the proton absorbed dose calculation and the neutron
equivalent dose calculation. (H/D)iso was 3.68 mSv/Gy for the water phantom plan (cf. Equation (2)),
using 140 MeV protons, i.e., entering the nozzle, with 5-cm range modulation, and a “medium” scattering
foil (specific to the MDACC design).
2.5. Calculation of Neutron Equivalent Dose Distribution in a Patient
To test the integration of the H/D model, ray tracing algorithm, and TPS, we prepared a treatment plan
using voxelized anatomic patient data. For this component of the study, we selected records for a young
woman who had received mediastinal irradiation for early stage Hodgkin lymphoma (HL). This patient
was selected for two reasons: (1) the treated anatomy provided clinically realistic features that were of
relevance to our study, e.g., irregular patient surfaces and internal tissue heterogeneities and (2) expected
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long survival time and therefore elevated risk of radiogenic late effects. In particular, HL patients
undergoing combined radiotherapy and chemotherapy may expect survival rates of approximately 90%
at 5 years and higher than 60% at 20 years [33,34]. Importantly, epidemiological studies have revealed
that HL patients treated with radiation are at increased risk of SMNs, e.g., cancer in the female breast,
lung, and thyroid [35].
The 26-year-old woman in our study had been diagnosed with stage IIB HL and had a solid
mediastinal tumor mass. She received passively scattered proton therapy at The University of Texas
MD Anderson Cancer Center in Houston, TX (MDACC). Data for this patient were collected under
a retrospective research protocol approved by our institutional review board. All protected health
information was removed from the electronic medical record using the methods of Newhauser et al. [36].
The treatment plan included a single anterior-posterior field to irradiate the tumor using 160 MeV protons
entering the nozzle, with 5.5-cm range modulation, 1.5-cm range shifter, and a medium scattering foil.
Proton absorbed dose was converted to equivalent dose using a mean radiation weighting factor of 1.
Equivalent dose distributions were computed separately for protons and neutrons and summed to find
the total equivalent dose distribution. For the HL patient, we applied a field-size correction factor to
our model for neutron equivalent dose. Specifically, we multiplied the (H/D)iso value of 5.09 mSv/Gy,
which was determined for this patient plan using Equation (2), by a factor of 0.623 that represented
the ratio of blocked-to-total area of the proton field incident on the patient-specific brass collimator.
This accounted for a decrease in neutron production in the treatment head when less collimation is
used, needed since the neutron model parameters from Pérez-Andújar et al. [28] were determined for
protons striking a closed collimator. Equivalent dose distributions were visualized using equivalent dose
colorwash planes, contour plots, and organ equivalent-dose volume statistics. To illustrate an out-of-field
organ at risk, we calculated the equivalent dose distribution in the thyroid. Calculation time was recorded
for both the proton absorbed dose calculation and the neutron equivalent dose calculation.
2.6. Comparison of Analytical H/D Model against a Monte Carlo H/D Model
We compared the H/D prediction against a Monte Carlo simulation of neutron equivalent dose for the
HL patient case described in the previous section. We used MCNPX (version 2.6, Los Alamos National
Laboratory, Los Alamos, NM, USA) [37]; and in-house codes [38] to simulate neutron transport and
energy deposition for neutrons produced in the MDACC proton treatment nozzle. In our simulation,
proton histories were terminated when they crossed a plane separating the treatment nozzle and the
patient; thus, we only simulated dose to the patient arising from neutrons produced in the nozzle.
The neutron absorbed dose calculated with Monte Carlo was converted to neutron equivalent dose using
a mean radiation-weighting factor for neutrons of 8, as determined by Newhauser et al. [17] for passively
scattered proton treatment of a medulloblastoma patient.
3. Results
3.1. Equivalent Dose Distributions in a Water-Box Phantom from the Analytical H/D Model
The equivalent dose distribution in the water phantom with the spherical target is plotted in Figure 1a.
As expected, the proton equivalent dose covered the spherical target uniformly, with a mean equivalent
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3.2. Equivalent Dose Distributions in a HL Patient from the Analytical H/D Model
3.2. Equivalent Dose Distributions in a HL Patient from the Analytical H/D Model
The equivalent dose distribution from a therapeutic proton beam in the HL patient is shown in
The equivalent dose distribution from a therapeutic proton beam in the HL patient is shown in Figure 2a.
Figure 2a. A mean equivalent dose of 36 Sv was seen in the target, falling off to zero dose approximately
A mean equivalent dose of 36 Sv was seen in the target, falling off to zero dose approximately 3.5 cm
3.5 cm laterally and 2.5 cm distally. The combined proton and neutron equivalent dose distribution is
laterally and 2.5 cm distally. The combined proton and neutron equivalent dose distribution is shown in
shown in Figure 2b. Similar to our observations for the water phantom, the target coverage was nearly
Figure 2b. Similar to our observations for the water phantom, the target coverage was nearly identical to
identical to that of proton dose only. Also consistent with our water phantom observation, the equivalent
that of proton dose only. Also consistent with our water phantom observation, the equivalent dose
dose distribution remained between 0.2% and 0.5% of the prescribed dose at large distances (≥15 cm)
distribution remained between 0.2% and 0.5% of the prescribed dose at large distances (≥15 cm) from
from the target boundary. For the HL patient, the proton equivalent dose calculation required 0.37 CPU
the target boundary. For the HL patient, the proton equivalent dose calculation required 0.37 CPU hours,
hours, and the neutron equivalent dose calculation required 0.63 CPU hours.
and the neutron equivalent dose calculation required 0.63 CPU hours.
To illustrate the spatial variation in the predicted equivalent dose distribution from neutrons, we
To illustrate the spatial variation in the predicted equivalent dose distribution from neutrons, we
plotted the neutron component alone in Figure 3a,c. The isodose contours are seen to diverge from
plotted the neutron component alone in Figure 3a,c. The isodose contours are seen to diverge from the
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Figure 2. Sagittal equivalent dose planes overlaying a thoracic CT image of the HL patient
Figure 2. Sagittal equivalent dose planes overlaying a thoracic CT image of the HL patient
showing (a) proton equivalent dose and (b) combined proton and neutron equivalent dose.
showing (a) proton equivalent dose and (b) combined proton and neutron equivalent dose.
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3.3. Dose Calculations Using the Analytical Model and Monte Carlo Simulations
3.3. Dose
Calculations Using the Analytical Model and Monte Carlo Simulations
Comparing H/D values from our analytical model with those from Monte Carlo simulations, we found

Comparing H/D values from our analytical model with those from Monte Carlo simulations, we
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thyroid equivalent dose of 120 ± 3 mSv, i.e., 0.3% of the prescribed dose (Figure 2b). In comparison, the
Monte Carlo H/D model predicted a thyroid equivalent dose of 86 ± 4 mSv. Our Monte Carlo simulation
of neutron equivalent dose required approximately 1600 CPU hours.
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We implemented an analytical model to calculate neutron equivalent dose using a proton radiotherapy
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One of the major clinical implications of this work is that this capability, with further development,
single CPU, a factor of 1.6 times that required for a typical therapeutic proton absorbed dose calculation.
mightItsomeday
enable clinicians
to routinely
consider quantitative
riskstreatment
of late effects
when
developing
appears straightforward
to integrate
H/D calculations
into the current
planning
workflow.
radiotherapy
treatment
plans.
approach
fast TPSs
neutron
i.e., less
than 1 h
The ability
to visualize
neutronOur
equivalent
doseprovides
in commercial
maycalculations,
encourage treatment
planning
on a modifications,
single CPU, such
a factor
of 1.6 timesor that
required
for a typical
therapeutic
absorbed
as repositioning
shielding
of out-of-field
organs
to reduce proton
exposures
without dose
affectingItdosimetric
coverage of the primary
target.H/D
Ourcalculations
comparison of
thethe
analytical
model with
calculation.
appears straightforward
to integrate
into
currentH/D
treatment
planning
workflow. The ability to visualize neutron equivalent dose in commercial TPSs may encourage treatment
planning modifications, such as repositioning or shielding of out-of-field organs to reduce exposures
without affecting dosimetric coverage of the primary target. Our comparison of the analytical H/D model
with the more accurate but computationally more expensive Monte Carlo simulations suggests that the
two approaches agreed within approximately 15% at the HL tumor isocenter and within 40% at the
thyroid. Some of the observed disagreement is likely due to the current approximation that all neutrons
diverge from a point in the patient collimator, whereas the more detailed Monte Carlo simulations model
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the neutron production in detail at multiple places throughout the nozzle, for example in the scattering
foils and trimmer-style collimators upstream of the patient collimator.
The current study had several limitations, but none of them prevented us from our primary objective,
which was to prove the feasibility of calculating out-of-field neutron dose using an analytical algorithm
suitable for inclusion in a current treatment planning process. First, our ray-tracing method, which
determined water-equivalent attenuation pathlengths for the neutron distributions, did not consider
the elemental composition of the patient but rather used tables designed to convert CT numbers to
water-equivalent pathlengths for proton range loss. Thus, the patient was ultimately assumed to consist
of voxels having different densities of water. A more physically realistic approach would be to use tables
explicitly designed to convert CT numbers to estimate elemental compositions of voxels and ultimately
equivalent attenuation pathlengths for neutrons. However, since the H/D values from the analytical and
Monte Carlo models agreed reasonably well, this approximation appears to have been appropriate for our
purposes, though this might also partially explain observed dosimetric discrepancies in air (cf. Figure 3)
where hydrogen itself is scarce and, thus, recoil-proton dose from neutron collisions is likely lower
than predicted when approximating air as very-low-density water. We remark that our Monte Carlo
simulations did, in fact, use a CT-to-elemental-composition table as described by Taddei et al. [25].
Second, since the vast majority of neutrons are assumed to emanate from plane of final collimation,
this method may not be directly applicable to modeling neutrons produced in the patient for a scanned
proton therapy system without substantial modification of the model. However, this too is not a serious
limitation because the vast majority of proton therapy (>95%) is delivered using passive scattering
treatment units. Some of the current limitations of the analytical H/D model are being addressed in
other studies in our laboratory, including generalization of the model for scanned beam therapy.
5. Conclusions
Our results demonstrate that it is feasible to predict neutron equivalent dose distributions using an
analytical dose algorithm for individual patients on a timescale comparable to that of routine proton
treatment-planning calculations. Eventually, personalized estimates of neutron equivalent dose to organs
far from the treatment field may guide clinicians to create treatment plans that reduce the risk of
late effects.
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